These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 23384836

  • 1. Inhibition of PI3K/AKT/mTOR pathway enhances temozolomide-induced cytotoxicity in pituitary adenoma cell lines in vitro and xenografted pituitary adenoma in female nude mice.
    Dai C, Zhang B, Liu X, Ma S, Yang Y, Yao Y, Feng M, Bao X, Li G, Wang J, Guo K, Ma W, Xing B, Lian W, Xiao J, Cai F, Zhang H, Wang R.
    Endocrinology; 2013 Mar; 154(3):1247-59. PubMed ID: 23384836
    [Abstract] [Full Text] [Related]

  • 2. Pyrimethamine sensitizes pituitary adenomas cells to temozolomide through cathepsin B-dependent and caspase-dependent apoptotic pathways.
    Dai C, Zhang B, Liu X, Guo K, Ma S, Cai F, Yang Y, Yao Y, Feng M, Bao X, Deng K, Jiao Y, Wei Z, Junji W, Xing B, Lian W, Wang R.
    Int J Cancer; 2013 Oct 15; 133(8):1982-93. PubMed ID: 23564480
    [Abstract] [Full Text] [Related]

  • 3. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 4. FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
    Wu Y, Dong L, Bao S, Wang M, Yun Y, Zhu R.
    Biomed Pharmacother; 2016 Dec 10; 84():462-469. PubMed ID: 27685789
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.
    Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA.
    Neuro Oncol; 2011 Apr 10; 13(4):384-92. PubMed ID: 21317208
    [Abstract] [Full Text] [Related]

  • 6. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
    Yu P, Laird AD, Du X, Wu J, Won KA, Yamaguchi K, Hsu PP, Qian F, Jaeger CT, Zhang W, Buhr CA, Shen P, Abulafia W, Chen J, Young J, Plonowski A, Yakes FM, Chu F, Lee M, Bentzien F, Lam ST, Dale S, Matthews DJ, Lamb P, Foster P.
    Mol Cancer Ther; 2014 May 10; 13(5):1078-91. PubMed ID: 24634413
    [Abstract] [Full Text] [Related]

  • 7. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
    Atif F, Patel NR, Yousuf S, Stein DG.
    PLoS One; 2015 May 10; 10(6):e0131441. PubMed ID: 26110872
    [Abstract] [Full Text] [Related]

  • 8. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH, Tian HY, Fung KP, Kurihara H, Pan JX, Ye WC.
    Carcinogenesis; 2013 Jun 10; 34(6):1331-42. PubMed ID: 23393227
    [Abstract] [Full Text] [Related]

  • 9. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA, Stechishin OD, Nguyen SA, Lun XQ, Cairncross JG, Weiss S.
    Clin Cancer Res; 2014 Nov 15; 20(22):5756-67. PubMed ID: 25316808
    [Abstract] [Full Text] [Related]

  • 10. Estrogen receptor β agonist enhances temozolomide sensitivity of glioma cells by inhibiting PI3K/AKT/mTOR pathway.
    Liu X, Wang L, Chen J, Ling Q, Wang H, Li S, Li L, Yang S, Xia M, Jing L.
    Mol Med Rep; 2015 Feb 15; 11(2):1516-22. PubMed ID: 25351348
    [Abstract] [Full Text] [Related]

  • 11. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
    Gravina GL, Mancini A, Scarsella L, Colapietro A, Jitariuc A, Vitale F, Marampon F, Ricevuto E, Festuccia C.
    Tumour Biol; 2016 Jan 15; 37(1):341-51. PubMed ID: 26219891
    [Abstract] [Full Text] [Related]

  • 12. Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.
    Zhao Y, Xiao Z, Chen W, Yang J, Li T, Fan B.
    Mol Med Rep; 2015 Aug 15; 12(2):2313-22. PubMed ID: 25937029
    [Abstract] [Full Text] [Related]

  • 13. LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway.
    Chen L, Han L, Shi Z, Zhang K, Liu Y, Zheng Y, Jiang T, Pu P, Jiang C, Kang C.
    Mol Med Rep; 2012 Feb 15; 5(2):575-9. PubMed ID: 22086271
    [Abstract] [Full Text] [Related]

  • 14. Curcumin sensitizes glioblastoma to temozolomide by simultaneously generating ROS and disrupting AKT/mTOR signaling.
    Yin H, Zhou Y, Wen C, Zhou C, Zhang W, Hu X, Wang L, You C, Shao J.
    Oncol Rep; 2014 Oct 15; 32(4):1610-6. PubMed ID: 25050915
    [Abstract] [Full Text] [Related]

  • 15. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK, Graab U, Fulda S.
    Cancer Lett; 2013 Sep 01; 337(2):200-9. PubMed ID: 23684925
    [Abstract] [Full Text] [Related]

  • 16. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K.
    Mol Cancer Res; 2013 Oct 01; 11(10):1269-78. PubMed ID: 23814023
    [Abstract] [Full Text] [Related]

  • 17. Synergistic anticancer efficacy of MEK inhibition and dual PI3K/mTOR inhibition in castration-resistant prostate cancer.
    Park H, Kim Y, Sul JW, Jeong IG, Yi HJ, Ahn JB, Kang JS, Yun J, Hwang JJ, Kim CS.
    Prostate; 2015 Nov 01; 75(15):1747-59. PubMed ID: 26250606
    [Abstract] [Full Text] [Related]

  • 18. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors.
    Ghadimi MP, Lopez G, Torres KE, Belousov R, Young ED, Liu J, Brewer KJ, Hoffman A, Lusby K, Lazar AJ, Pollock RE, Lev D.
    Mol Cancer Ther; 2012 Aug 01; 11(8):1758-69. PubMed ID: 22848094
    [Abstract] [Full Text] [Related]

  • 19. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.
    Clin Cancer Res; 2011 Aug 15; 17(16):5322-32. PubMed ID: 21712451
    [Abstract] [Full Text] [Related]

  • 20. Nelfinavir induces radiation sensitization in pituitary adenoma cells.
    Zeng J, See AP, Aziz K, Thiyagarajan S, Salih T, Gajula RP, Armour M, Phallen J, Terezakis S, Kleinberg L, Redmond K, Hales RK, Salvatori R, Quinones-Hinojosa A, Tran PT, Lim M.
    Cancer Biol Ther; 2011 Oct 01; 12(7):657-63. PubMed ID: 21811091
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.